Royalty Pharma plc (RPRX)
| Market Cap | 29.37B |
| Revenue (ttm) | 2.38B |
| Net Income (ttm) | 770.95M |
| Shares Out | 592.82M |
| EPS (ttm) | 1.78 |
| PE Ratio | 27.73 |
| Forward PE | 9.68 |
| Dividend | $0.94 (1.90%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 3,491,524 |
| Open | 49.90 |
| Previous Close | 49.65 |
| Day's Range | 49.34 - 49.90 |
| 52-Week Range | 31.97 - 50.25 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 51.40 (+3.74%) |
| Earnings Date | May 6, 2026 |
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune ... [Read more]
Financial Performance
In 2025, Royalty Pharma's revenue was $2.38 billion, an increase of 5.06% compared to the previous year's $2.26 billion. Earnings were $770.95 million, a decrease of -10.25%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price target is $51.4, which is an increase of 3.74% from the latest price.
News
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in transl...
Royalty Pharma Declares Second Quarter 2026 Dividend
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ord...
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. fi...
Royalty Pharma and J&J partner to develop autoimmune treatment
Royalty Pharma said on Monday it has signed a $500 million research and development agreement with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases.
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million ...
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead ...
Royalty Pharma Announces Expansion of Leadership Team
Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments
Royalty Pharma Transcript: TD Cowen 46th Annual Health Care Conference
Management outlined strategic expansion in Asia, highlighted major royalty deals, and reaffirmed long-term revenue and capital deployment targets. The business model emphasizes diversification, high margins, and disciplined growth, with strong returns and ongoing investment in technology.
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be...
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zymeworks Inc. (Nasdaq: ZYME) today announced an agreement for $250 million in fundin...
Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference
NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3, 2...
Royalty Pharma Earnings Call Transcript: Q4 2025
Delivered double-digit growth in portfolio and royalty receipts for 2025, surpassing guidance and achieving strong returns. Internalization of the manager drove cost savings, while capital deployment and shareholder returns hit record levels. Robust 2026 guidance reflects continued momentum.
Royalty Pharma Reports Q4 and Full Year 2025 Results
Portfolio Rece ipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025 Net cas h provided by operating activities of $827 million...
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 202...
Royalty Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong 2025 performance was driven by robust capital deployment, innovative synthetic royalty deals, and a disciplined investment process. The company targets $4.7B+ top line by 2030, with significant growth expected from both current assets and new deals, and sees major opportunities in China and synthetic royalties.
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva's an...
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharm...
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEV...
Royalty Pharma Announces Dividend Increase
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A or...
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 ...
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an und...
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic roya...
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royal...
Royalty Pharma Transcript: Evercore ISI 8th Annual HealthCONx Conference
A transformational year included a major strategic consolidation, record capital returns, and strong financial performance. Portfolio growth is driven by both existing and new assets, with innovative deal structures like the RevMed transaction setting new industry precedents. Key milestones ahead include major clinical readouts and international expansion initiatives.
Royalty Pharma Transcript: Citi Annual Global Healthcare Conference 2025
Internalization and aggressive share buybacks marked a strategic shift, while deal flow and capital deployment momentum increased. The company maintains a balanced, broad investment approach, leverages creative deal structures, and expects continued growth in royalty partnerships and market size.